Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.
Introduction
Crohn's disease [CD] is a chronic inflammatory bowel disease characterised by transmural inflammation which presents as one of three phenotypes: inflammatory, fibrostenotic, or fistulising disease. Perianal fistulising CD, one the most common disease manifestations, remains a significant clinical challenge and greatly affects patients' quality of life due to pain, discharge, and abscess formation [ Figure 1 ]. 1 This morbidity often results in difficulty in maintaining a job and decreased quality of life. At least 26% of CD patients develop perianal fistulas in the first two decades following diagnosis, [2] [3] [4] [5] particularly those with colonic and rectal involvement. 5 Achieving complete fistula healing is commonly an arduous process involving multiple medical and surgical treatments followed by multiple relapses. Patients frequently fail to respond to current treatment strategies including antibiotics, immunosuppressive agents, and biologic therapy. [6] [7] [8] The multitude of surgical interventions do not offer more promising treatment results and have the added risk of incontinence. In more severe cases, faecal diversion may be used to quiet the disease, but recurrence is high with restoration of continuity, and up to 20-40% will eventually undergo a proctectomy. 9, 10 Unfortunately, despite the best available therapies, durable remission rates of complex perianal fistula remain as low as 37%. 11 These findings underscore the need for alternative therapies.
An emerging therapeutic approach for perianal fistulising CD is the use of mesenchymal stem cells [MSCs] . These are non-haematopoietic multipotent cells able to down-regulate immune responses and promote tissue healing. Studies have shown that human MSCs inhibit the generation of dendritic cells from monocytes, suppress naïve and memory CD4+ cells, prevent T cell activation by downregulating costimulatory molecules on mature dendritic cells, and promote the generation of regulatory T cells. [12] [13] [14] [15] [16] [17] Additionally, MSCs are able to migrate to the site of injury, 18 becoming key players in tissue repair processes, all of which provide strong evidence suggesting investigation of the use of these cells for perianal CD. Recently, several clinical trials have been conducted with both autologous and allogeneic adipose tissue-derived and bone marrow-derived MSCs, to determine the safety and efficacy of treating perianal CD. The results are promising, with significantly increased rates of healing as compared with conventional therapy. The aim of this review is to present previous, ongoing, and future efforts toward achieving improved healing of perianal CD.
Medical Therapy
Perianal CD remains largely refractory to conventional medical therapy, with two-thirds of patients relapsing [19] [20] [21] [22] [23] and only a third maintaining long-term remission. 11 Since the advent of biologic therapy with infliximab (an anti-tumour necrosis factor-α [TNFα]), there has been a modest improvement in the medical management of perianal CD, and current consensus made by a global working group states that anti-TNFα is the current gold standard for medical management following drainage of any associated abscess. 24 The 'A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen in Patients with Fistulizing Crohn's Disease' [ACCENT II] trial, evaluating the efficacy of infliximab in maintaining closure of draining perianal fistulas, found 36% of patients had complete cessation of drainage of perianal fistulas at 54 weeks 25 as compared with 19% in the control cohort [p = 0.009]. A recently published meta-analysis, including 453 patients with active perianal fistulising CD, confirmed these findings─complete closure of the fistula was observed in only 33% of the patients after anti-TNF therapy alone. 8 The 'Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance' [CHARM] was a large, phase III, randomised, double-blind, placebo controlled, 56-week study of patients with moderate to severe CD, who may or may not have received previous anti-TNF therapy. When performing an analysis for perianal fistula healing at 56 weeks, 33% of treated patients had fistula healing as compared with 13% of controls [p < 0.05], and 90% of the healed patients had sustained healing at 1 year following the 56-week endpoint. 26 For anti-TNF naïve patients, a multicentre retrospective review found that adalimumab had sustained healing to 1 year in 41% of patients. 27 Recently, Sandborn et al. 28 reported the results of the first induction and maintenance trials of vedolizumab, an α4B7-integrin antibody. Although the number of patients with fistulas in this trial was quite low, vedolizumab administered every 8 weeks resulted in a significant higher closure rate of 41% compared with placebo [11.1%; p = 0.03].
Surgical Therapy
Perianal fistulas are classified as simple or complex, or by the relationship to the anal sphincter complex. Simple fistulas are those that only involve the lower one third of the external sphincter 24 and are painless, with a single external opening and no evidence of rectovaginal involvement or anorectal stricture. 2 The definition of a complex fistula is not standardised, but most agree on any fistula that is high trans-sphincteric or when a fistulotomy would result in incontinence, e all those caused by CD, those associated with pain or with multiple external openings, those involving a rectovaginal component, or those with anorectal stricture or active proctitis.
Park's classification of perianal CD classifies anal fistulas based on their relationship to the anal sphincter complex. 29 The nomenclature reflects the fistula's relationship to the external sphincter: intersphincteric, trans-sphincteric, suprasphincteric, and extrasphincteric [ Figure 2 ]. An intersphincteric fistula occurs in 20% to 45% of cases and does not penetrate the external sphincter. A trans-sphincteric fistula occurs in 30% to 60% of cases and penetrates the external sphincter below the level of the puborectalis muscle, exiting into varying levels within the ischiorectal fossa. A suprasphincteric fistula occurs in 20% of cases, and describes a fistula tract that is over the top of the puborectalis, then downward again through the levator plate to the ischiorectal fossa and finally out through the skin. An extrasphincteric fistula, the least common, occurring in 2% to 5% of cases, passes from the perineal skin through the ischiorectal fat and levator muscles into the rectum.
There are several surgical options for perianal CD, but most are limited by the risk of non-healing and the potential for faecal incontinence. 30 Fistulectomy and fistulotomy are preferred for superficial simple fistulas and low intersphincteric fistulas in patients without CD, and result in healing rates up to 100%. These techniques are rarely used in patients with CD, however, due to concerns regarding non-healing and potential incontinence. 2 Less invasive surgical options include long-term seton placement for drainage, fibrin glue injection, or insertion of a fistula plug with or without concurrent medical therapy. Seton placement with concurrent medical therapy has been one of the most widely used and successful treatments for perianal CD. CD patients treated with infliximab and non-cutting seton placement had better outcomes than patients treated with infliximab alone, with 47% perineal healing at 20 months, 31 decreased recurrence rate [44% vs 79%, p = 0.001], and increased time to recurrence [13.5 months vs 3.6 months, p = 0.0001]. 32 To date, the optimal timing of seton removal has not been clearly established. In the intital studies, 25, 31, 32 setons were removed at the time of the second infliximab infusion, but more recent evidence shows that seton removal after the complete induction of infliximab 33 or at least after five infliximab infusions 34 ensures a lower recurrence rate. In terms of fibrin glue, a randomised controlled trial [RCT] documented clinical remission in 38% of the fibrin glue group, compared with 16% in the observation group at Week 8. However, at long-term follow up [median 37 months] only 20% were in remission. 35 Similarly, early studies with the Surgisis® anal fistula plug seemed promising with healing rates up to 80-86%, but more recent studies demonstrate a more dismal rate of 25-50%. [36] [37] [38] [39] For patients who do not respond to these less invasive surgical techniques, a rectal advancement flap or ligation of the intersphincteric fistula tract [LIFT] 40 may be considered. A rectal advancement flap is associated with a 64% healing rate but 10% risk of incontinence. 30, 41 The LIFT procedure has been associated with 67% healing rates at 12 months without any documentation of incontinence. 40 For patients with refractory disease, a diverting ileostomy or proctectomy may become the only available options. Symptomatic improvement occurs in up to two-thirds of patients with diversion, but disease recurrence reaches 80% following ileostomy reversal, and up to 40% of patients who fail diversion will ultimately undergo a proctectomy. 30 Thus the most advanced medical and surgical therapies to date lead to 1-year remission rates of 40-50%, indicating a significant medical need for optimised therapy for perianal fistulas in the setting of CD.
Stem Cell-based Therapy
Mesenchymal stem cells offer a promising alternative to the traditional medical and surgical interventions. To date, several phase I, II, and III trials have demonstrated safety and efficacy with local administration of autologous or allogeneic adipose tissue-and bone marrow-derived MSCs into the perineal fistulas of CD patients [ Table 1 ]. Initial studies had dramatically improved healing rates, which may in fact be an overestimation since efficacy was not determined by both clinical and radiographic findings but byclinical examination alone. That said, almost all patients enrolled in these trials were refractory to standard therapy, and regardless of the origin of the MSCs, or the dose and method of administration, results have largely suggested superior efficacy compared with conventional therapy in a difficult to treat subgroup.
To date, more than 200 patients with refractory fistulising perianal CD have been treated with local injection of MSCs. More than half of patients have experienced a complete clinical response and this is sustained to at least for months in the majority of patients. Due to the ongoing success of treatments, additional clinical trials are being performed to further investigate the use of MSCs for perianal CD [ Table 2 ].
Autologous stem cells
The pioneering clinical trial work of using MSCs for the treatment of perianal CD was reported by Garcia-Olmo et al., and was published as a case report of the successful treatment of a rectovaginal fistula at 1 week following the injection of MSCs derived from adipose tissue. 42 Garcia-Olmo et al. then performed a phase I study, treating four patients suffering from one or more refractory complex Crohn's fistulas, with a single fistula tract injection of 3 x 10 6 autologous adipose tissue-derived MSCs. The authors observed healing in three of four [75%] of patients at 8 weeks, and there were no adverse effects at the 12-and 22-month follow-up visits. 43 In the later phase IIb trial by the same group, 49 patients with complex perianal cryptoglandular and CD fistulas were randomly assigned to treatment with fibrin glue alone vs fibrin glue with 2 x 10 6 adipose tissue-derived MSCs; patients in the MSC group received a second dose of 4 x 10 6 MSC if fistula healing was not seen at 8 weeks. In patients with CD, fistula healing at 1 year occurred in 71% [n = 5 of 7] in the MSC group as compared with 14% [n = 1 of 7] in the control group. Regardless of fistula healing, as defined by cessation of drainage and complete epithelialisation of the external opening, quality of life was significantly improved in the MSC group. 44 Another group performed a small dose-escalation phase I study, in which 10 patients with perianal CD fistulas were treated with direct injection of autologous adipose tissue-derived MSCs at doses of 1 x 10 7 , 2 x 10 7 , 4 x 10 7 cells/ml, based on the size of the fistula [total of 3-40 x 10
7 cells]. After 8 weeks, complete external epithelisation of the fistula tract was observed in 30% [n = 3 of 10; 2 of the 2 x 10 7 group and 1 of the 4 x 10 7 group], whereas partial closure with no drainage was observed in all other patients. These results were sustained after 8 months. 45 The same group then led a phase II trial, with 33 treated patients. The first direct injection was with a number of MSCs proportionate to the size of the fistula [ 
Allogeneic stem cells
Autologous cells theoretically have a lower rate of rejection and better tolerability, but they require additional steps including fat pad or bone marrow harvest, expansion, and occasional thawing. This means they cannot be generated and inserted within the same operation. The potential of having a ready-to-use MSC preparation directly at the patient bedside circumvents these extra steps and therefore has the potential to treat greater numbers of patients and/ or prevent delays in treatment. Unfortunately, relative safety and efficacy studies comparing autologous with allogeneic cells have yet to be performed. Thus, we do not yet understand which cell type is superior to the other in terms of healing rates.
There have now been phase I, II, and III clinical trials investigating allogeneic adipose tissue-derived MSCs and one phase II study investigating allogeneic bone marrow-derived MSCs for the treatment of perianal fistulas. In the single-arm, multicentre, phase I/IIa clinical trial, 24 patients received a direct injection of 2 x 10 6 allogeneic adipose tissue-derived MSCs, followed by a second administration of 4 x 10 6 MSCs if fistula closure remained unsuccessful at Week 12. Complete fistula closure, as defined by absence of suppuration through the external orifice and complete re-epithelisation, occurred in 38% [ The effects were maintained to Week 24. Of the various attempted dosages, 3 x 10 7 had the best treatment effects, and no dosage was associated with any increased observed adverse events. 49 
Ongoing Trials
There are currently five ongoing clinical trials, four of which are addressing autologous MSC therapy and one of which is studying allogeneic MSC therapy [ Table 2 ]. Of the autologous MSC therapy, the phase I study from the Mayo Clinic is investigating the safety and efficacy of a novel therapeutic design. Investigators are harvesting adipose tissue-derived autologous MSC from a fat pad biopsy, and then placing the cells onto a Gore® Bio-A® Fistula Plug [Gore plug; W. L. Gore and Associates, Newark, DE] at a concentration of approximately 20 million per plug. The plug is then tailored at the time of insertion for placement into the fistula tract. To date, at 6 months, 83% [13 of 15 patients] have achieved complete clinical healing [cessation of drainage to deep palpation] and radiographic healing by MRI, suggesting that this novel delivery mechanism may offer improved efficacy as compared with direct injection. 50 The other four ongoing trials are again investigating direct injection of cells. 
Mechanism of MSCs
MSCs can be isolated from bone marrow, adipose tissue, umbilical cord, placenta, or the connective tissue of most organs. 51, 52 MSCs are considered immunoprivileged because they express low levels of human leukocyte antigen [HLA] class I and do not express class II or costimulatory molecules [CD80, CD86, or CD40]. 53, 54 The exact mechanism by which MSCs heal perianal fistulas remains unknown, and the clinical trials to date have not studied the mechanistic aspects of this treatment. What is known is that MSCs have important immunomodulatory and anti-inflammatory effects: MSCs inhibit the generation of dendritic cell maturation from monocytes, suppress naïve and memory CD4+ cells, suppress CD8+ T-cell proliferation and differentiation, and promote the generation of T regulatory cells [12] [13] [14] [15] [16] [17] from both naïve and memory T cells. 55 In CD, antigen-presenting cells, such as dendritic cells, are responsible for the generation of T cell responses. In addition, T regulatory cells are down-regulated and lower in the peripheral blood. 56 In vitro, MSCs not only inhibit dendritic maturation but also induce them into a regulatory-like profile. 57 Similarly, MSCs recruit T regulatory cells, shift the T cell population toward a more tolerogenic pattern, 58 ,= and shift the macrophage phenotype to an anti-inflammatory [M2] rather than an inflammatory [M1] pattern. 59 Thus, an important component of MSC-mediated immunomodulation may result from creating a regulatory-like phenotype.
To assist in tissue repair, MSCs migrate selectively to sites of tissue injury and inflammation. [60] [61] [62] It is unclear how long MSCs stay at the site of injury, but there is some evidence to suggest that MSCs stay in the colon for at least 15 days after injection. 63 At the site of injury, MSCs are able to differentiate into various cell types and engraft into many tissues [64] [65] [66] where they can promote tissue repair. [67] [68] [69] [70] [71] [72] [73] In vitro, to exert their full potential, MSCs need to first be activated by inflammatory signals and then establish close cell-tocell contact with target cells, underscoring their effectiveness at sites of inflammation. 58 What remains unknown is the optimal delivery and concentration of MSCs to support homing and engraftment for therapeutic use.
Origin of MSCs
The studies discussed above have included both autologous and allogeneic MSCs, both of which have advantages and disadvantages. The thought is that autologous cells are less immunogenic, coming from the patient's own cell line. However, the logistics of cellular delivery are cumbersome, requiring a procedure for cellular harvest followed by the need to expand and later deliver the cells. In contrast, allogeneic cells are available at the time of patient availability, and require less infrastructure to generate than autologous cells. However, there is a theoretical risk they are increasingly immunogenic, despite the low expression of HLA.
Seven of the nine completed clinical trials were performed using adipose tissue-derived MSCs, [43] [44] [45] 48, 74, 75 whereas the other two used bone marro-derived MSCs. 47, 49 The advantage of adipose tissuederived MSCs is the accessibility to large numbers of cells, using minimally invasive procedures including liposuction. Additionally, a recent study demonstrated that adipose tissue-and bone marrowderived MSCs from the same donor have similar immunomodulatory capacity on both innate and acquired immunity cells. 76 However, studies comparing their efficacy in vivo have yet to be performed, and may help answer the question of which cell type is superior for therapeutic use. 
Optimal Dose and Dosing Interval

Cellular Delivery
All completed clinical trials have delivered the MSCs with or without fibrin glue, via direct injection into the fistula tract after closure of the internal opening. The ongoing trial by our group at the Mayo Clinic is using a Gore® Bio-A® Fistula Plug for cellular delivery. It remains unknown where a scaffold delivers a higher concentration of cells over a greater duration or whether the scaffolding changes the cellular phenotype. Ongoing investigation regarding optimal cellular delivery will help guide optimal treatment protocols.
Safety
Adverse events [AEs] , and serious adverse events [SAEs; defined as events that were fatal or life-threatening, led to hospitalisation or disability, or required an intervention to prevent one of these outcomes] are recorded among all clinical trials to assess safety. In the clinical trials reported herein, no AE or SAE reported has been related to MSCs.
In the phase I clinical trial by Garcia-Olmo et al., 43 there were no reported AEs in the four patients treated by direct injection of MSCs. In the subsequent phase II clinical trial by Garcia-Olmo et al., 44 there were a total of 24 non-serious AEs, of which 15 were in the group treated with fibrin glue alone and nine in the MSC-treated patients. Half of the cases were perianal sepsis. There were four SAEs, of which one event was treatment-related [perianal abscess] in the fibrin glue-treated group. No adverse events related to MSC injection were seen after a mean of 40 months post injection. 74 In the phase I trial by Cho et al., 45 
Future Directions
Several questions regarding MSCs for perianal CD remain unanswered. First, it will be important to determine the clinical efficacy of MSCs in CD patients with active proctitis, given most trials excluded these patients. Second, the optimal treatment dosage of MSCs remains unknown and will be important for optimising outcomes. Third, the optimal approach of cellular delivery remains unknown─direct injection, fibrin glue, or attached to a bioabsorbable matrix. Fourth, randomised controlled trials to decipher whether autologous or allogeneic cells are more efficacious will be important. Fifth, further investigation as to whether MSCs are equally efficacious in healing rectovaginal as enterocutaneous fistulas in CD may have important treatment implications. Sixth, direct comparison between MSCs with biologic therapy or alternative surgical treatment options will be important, to determine if there is improved therapeutic efficacy. Last, it will be perhaps most importantto investigate the mechanism by which MSCs heal perianal fistulas. Understanding the mechanism will allow for an optimised approach for future intervention.
Conclusions
Treatment of perianal fistulas in the setting of CD is notoriously difficult, and the efficacy of conventional treatment approaches remains limited. The use of MSCs offers a safe and promising treatment alternative, due to improved treatment efficacy without the risks of systemic side effects or faecal incontinence. There are now several phase I, II, and III trials which have demonstrated good outcomes with both autologous and allogeneic MSCs derived from both adipose tissue and bone marrow tissue. Whereas MSCs enlarge the therapeutic arsenal for perianal fistulas, the specific mechanism of action remains unknown. Future study may shed light as to why these cells improve healing and how we can optimise cell type, dosing, and mode of delivery, to further improve healing rates and optimise outcomes.
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